Journal article

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

CR Divgi, NH Bander, AM Scott, JA O'Donoghue, G Sgouros, S Welt, RD Finn, F Morrissey, P Capitelli, JM Williams, D Deland, A Nakhre, E Oosterwijk, S Gulec, MC Graham, SM Larson, LJ Old

Clinical Cancer Research | Published : 1998

Abstract

This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. Thirty-three patients with measurable metastatic renal cell carcinoma were treated. Groups of at least three patients received escalating amounts of 1311I (30, 45, 60, 75, and 90 mCi/m2) labeled to 10 mg of mouse monoclonal antibody G250, administered as a single i.v. infusion. Fifteen patients were studied at the MTD of activity. No patient had received prior significant radiotherapy; one had received prior G250. Whole-body scintigrams and single-photon emission computed tomography images were obtained in all patients. There was targeting of radioact..

View full abstract

University of Melbourne Researchers